Climb Bio (CLYM) Preferred Dividend Payments (2020 - 2021)
Climb Bio (CLYM) reported Preferred Dividend Payments of $1.3 million for Q3 2021, up 186.77% on a YoY basis from $461000.0 in Q3 2020, and down 38.25% quarter-over-quarter from $2.1 million in Q2 2021.
Climb Bio (CLYM) Preferred Dividend Payments (2020 - 2021) Analysis & Trends
Climb Bio has reported Preferred Dividend Payments for 2 years, with the latest figure at $1.3 million in Q3 2021.
- For the quarter ending Q3 2021, Preferred Dividend Payments rose 186.77% year-over-year to $1.3 million; the trailing twelve-month figure through Jun 2022 stood at $1.3 million (down 71.39% YoY), and the FY2021 full-year result was $4.5 million, up 99.04% from the prior year.
- Preferred Dividend Payments for Q3 2021 stood at $1.3 million, down from $2.1 million in the prior quarter.
- The five-year high for Preferred Dividend Payments was $2.1 million in Q2 2021, with the low at $452000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Climb Bio | 774.84 Mn | 774.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 1.32 Mn |
| Jun 30, 2021 | 2.14 Mn |
| Mar 31, 2021 | 1.09 Mn |
| Dec 31, 2020 | 933,000.00 |
| Sep 30, 2020 | 461,000.00 |
| Jun 30, 2020 | 452,000.00 |